MEN 1703 is a first-in-class orally available dual PIM and FLT3 kinase inhibitor discovered by Selvita and acquired by the Menarini Group at the beginning of 2017.
The molecule has a unique activity profile for its ability of inhibiting both PIM kinase, important for cell cycle regulation, cell survival and tumorigenesis, and FLT3, a kinase involved in the onset and progression of acute myeloid leukemia (AML).
None of the molecules currently in clinical development has this dual activity.
MEN1703 started the Phase I/II clinical trial in patients with relapsed /refractory AML in March 2017.
Preclinical evidence supports clinical development not only in hematological tumors but also in solid tumors.
Technology Transfer of the manufacturing process from Selvita to Menarini is ongoing as well as preclinical studies aimed to support the design of additional clinical trials in AML and the selection of further indications in solid tumors and hematological malignancies.